C12-TLRa

C12-TLRa is an adjuvant lipidoid (pKa = 6.42) with toll-like receptor 7/8 (TLR7/8) agonist activity. Lipid nanoparticles (LNPs) containing C12-TLRa as a partial replacement for the ionizable lipidoid C12-113 (Cay-39335) and encapsulating luciferase mRNA exhibit TLR7 agonist activity in HEK reporter cells and induce TNF-alpha production in DC2.4 cells. LNPs containing C12-TLRa and encapsulating luciferase mRNA have improved mRNA transfection and duration and induce a larger increase in the percentage of mature dendritic cells in mice when compared to LNPs containing C12-113. A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-LNP vaccine containing C12-TLRa induces higher serum IgG titers to the SARS-CoV-2 receptor-binding domain (RBD), as well as a higher number of CD80+PD-L2+ RBD-specific B cells, in the spleen in mice.Formal Name: 1,1'-((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)azanediyl)bis(dodecan-2-ol). Synonyms: C12-Toll-Like Receptor a. Molecular Formula: C46H73N5O2. Formula Weight: 728.1. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: Chloroform: Slightly Soluble: 0.1-1 mg/ml, DMSO: Sparingly Soluble: 1-10 mg/ml, Methanol: Slightly Soluble: 0.1-1 mg/ml. SMILES: NC1=NC2=CC=CC=C2C3=C1N=C(N3CC4=CC=C(C=C4)CN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)CCCC. InChi Code: InChI=1S/C46H73N5O2/c1-4-7-10-12-14-16-18-20-24-39(52)35-50(36-40(53)25-21-19-17-15-13-11-8-5-2)33-37-29-31-38(32-30-37)34-51-43(28-9-6-3)49-44-45(51)41-26-22-23-27-42(41)48-46(44)47/h22-23,26-27,29-32,39-40,52-53H,4-21,24-25,28,33-36H2,1-3H3,(H2,47,48). InChi Key: HIHJXHDBDZYVSP-UHFFFAOYSA-N.